185 related articles for article (PubMed ID: 24812044)
1. Disease modifying therapies in multiple sclerosis: could a baseline thyroid check-up drive the therapeutic choice between interferon-β and glatiramer acetate?
Rotondi M; Bergamaschi R; Chiovato L
Mult Scler; 2014 Dec; 20(14):1918-9. PubMed ID: 24812044
[No Abstract] [Full Text] [Related]
2. The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
Duddy M; Palace J
Pract Neurol; 2016 Feb; 16(1):4-6. PubMed ID: 26430247
[No Abstract] [Full Text] [Related]
3. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
4. Multiple sclerosis disease-modifying therapy and pregnancy.
Miller AE
Mult Scler; 2016 May; 22(6):715-6. PubMed ID: 27207870
[No Abstract] [Full Text] [Related]
5. [New active substances expand the treatment options for MS].
Hellwig B
Med Monatsschr Pharm; 2015 Feb; 38(2):65-8. PubMed ID: 26376542
[No Abstract] [Full Text] [Related]
6. [Effect of glatiramer acetate (copaxone) on the structure and functions of the thyroid gland in patients with multiple sclerosis].
Petrova LV; Boĭko AN; Batysheva TT; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):41-5. PubMed ID: 21311486
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs.
Tsareva E; Kulakova O; Boyko A; Favorova O
Pharmacogenet Genomics; 2016 Mar; 26(3):103-15. PubMed ID: 26678572
[TBL] [Abstract][Full Text] [Related]
8. [Hepatitis induced by glatiramer acetate].
Fernández Fernández N; Joao Matias D; Pisabarros Blanco C; Rodríguez Martín L; Aparicio Cabezudo M; Linares Torres P; Hernando Martín M; Olcoz Goñi JL
Gastroenterol Hepatol; 2015 Apr; 38(4):280-1. PubMed ID: 25042243
[No Abstract] [Full Text] [Related]
9. Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice.
Meca-Lallana J; Hernández L; Caminero AB; Girón JM; Cano-Orgaz A; Carcelén-Gadea M; Muñoz D; Durán-Ferreras E; Martín-Hernández J; Sánchez-de la Rosa R;
Eur Neurol; 2016; 76(1-2):40-7. PubMed ID: 27376845
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?
Garattini L; Ghislandi F; Da Costa MR
Pharmacoeconomics; 2015 Dec; 33(12):1241-4. PubMed ID: 26293887
[No Abstract] [Full Text] [Related]
11. Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective study.
Durelli L; Ferrero B; Oggero A; Verdun E; Ghezzi A; Montanari E; Zaffaroni M;
J Clin Endocrinol Metab; 2001 Aug; 86(8):3525-32. PubMed ID: 11502774
[TBL] [Abstract][Full Text] [Related]
12. Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
O'Connor P;
Neurology; 2002 Sep; 59(6 Suppl 3):S1-33. PubMed ID: 12448786
[No Abstract] [Full Text] [Related]
13. Spasticity in multiple sclerosis and role of glatiramer acetate treatment.
Meca-Lallana JE; Hernández-Clares R; Carreón-Guarnizo E
Brain Behav; 2015 Sep; 5(9):e00367. PubMed ID: 26445705
[TBL] [Abstract][Full Text] [Related]
14. [The pegylated form of interferon beta in the treatment of multiple sclerosis].
Melnikov MV; Kasatkin DS; Volkov AI; Boyko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(8):136-141. PubMed ID: 31626182
[TBL] [Abstract][Full Text] [Related]
15. Clinical markers of therapeutic response to disease modifying drugs.
Pozzilli C; Prosperini L
Neurol Sci; 2008 Sep; 29 Suppl 2():S211-3. PubMed ID: 18690494
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.
Healy BC; Glanz BI; Zurawski JD; Mazzola M; Chitnis T; Weiner HL
J Neurol Sci; 2018 Nov; 394():127-131. PubMed ID: 30248571
[TBL] [Abstract][Full Text] [Related]
17. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].
Gusev EI; Boĭko AN; Pozer Ch
Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395
[No Abstract] [Full Text] [Related]
18. The use of interferon Beta and glatiramer acetate in multiple sclerosis.
Goodin DS
Semin Neurol; 2013 Feb; 33(1):13-25. PubMed ID: 23709209
[TBL] [Abstract][Full Text] [Related]
19. [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].
Federal service on surveillance in healthcare and social development (Roszdravnadzor)
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):86-92. PubMed ID: 21916162
[TBL] [Abstract][Full Text] [Related]
20. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
Federal service on surveillance in healthcare and social development (Roszdravnadzor)
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
[No Abstract] [Full Text] [Related]
[Next] [New Search]
